Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

This publication has 37 references indexed in Scilit:

• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
  EMBO Molecular Medicine, 2009
• Functional Restoration of BRCA2 Protein by SecondaryBRCA2Mutations inBRCA2-Mutated Ovarian Carcinoma
  Cancer Research, 2009
• Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
  Cancer Research, 2008
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
  Nature, 2008
• Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer
  Proceedings of the National Academy of Sciences, 2007
• Genome-wide association study identifies novel breast cancer susceptibility loci
  Nature, 2007
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy
  Nature Reviews Cancer, 2005
• Breast cancer and hormone-replacement therapy in the Million Women Study
  The Lancet, 2003
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Identification of the breast cancer susceptibility gene BRCA2
  Nature, 1995